J&J looks to toss its SGLT2 hat in the ring for two types of heart failure
In the last year, two SGLT2 inhibitors — initially developed to treat diabetes — have snagged approvals in the heart failure space. Now Johnson & Johnson is jumping on the bandwagon, reading out positive Phase III results for its own SGLT2 drug Invokana.
Patients who took Invokana in the CHIEF-HF study saw “significantly greater improvements” in their heart failure symptoms compared to placebo, regardless of their diabetes status, J&J announced at this year’s American Heart Association conference.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
